Non-vitamin K Oral Anticoagulants in Cardioversion

Completed

• Conditions: Atrial Fibrillation

• Registration Number: NCT02911545
• Lead Sponsor: Helsinki University Central Hospital

Brief Summary

Non-vitamin K oral anticoagulants (NOAC) have been shown to be safe and effective alternatives to warfarin for stroke prevention in patients with nonvalvular AF (NVAF). There are yet limited real life data on outcomes following elective cardioversion in AF patients treated with NOACs. The aim of this study is to investigate the complications and the use of NOACs in AF patients undergoing cardioversion.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-10
• Primary Completion: 2015-12
• Study Completion: 2016-05
• Status Verified: 2016-09
• Study First Submitted: 2016-09-16
• Study First Submitted QC: 2016-09-21
• Last Update Submitted: 2016-09-21
• Study First Posted: 2016-09-22
• Last Update Posted: 2016-09-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• AF patients undergoing cardioversion

Exclusion Criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence and predictors of thromboembolic complications	31 days after cardioversion of persistent AF
Incidence and predictors of bleeding	31 days after cardioversion of persistent AF

Secondary Outcome Measures

Name	Time	Method
Hemodynamic complications of cardioversion	31 days after cardioversion of persistent AF
Number of recurrence of AF	31 days after cardioversion of persistent AF